Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981526 · ClinicalTrials.gov registry record · Phase 4
Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
A Phase 4 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT00981526 is a Phase 4 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 66 participants.
The verdict
NCT00981526, a Phase 4 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a 12-week, randomized, double-blinded, placebo-controlled trial of telmisartan 80 mg/day as an adjunctive to clozapine or olanzapine therapy, in 70 schizophrenia subjects to examine telmisartan's effect on glucose metabolism, weight, food intake, resting energy expenditure, and body composition. In addition, the study will examine insulin's effects on psychopathology and cognition. Potential subjects will be identified by their clinicians at the Freedom Trail Clinic, or Massachusetts General Hospital. Approximately 70 subjects will be enrolled.
Interventions
- DRUG Placebo
- DRUG Olanzapine
- DRUG Clozapine
- DRUG Telmisartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00981526
The ClinicalTrials.gov registry entry for NCT00981526 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00981526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00981526 about?
NCT00981526 is a clinical study titled "Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia". This is a 12-week, randomized, double-blinded, placebo-controlled trial of telmisartan 80 mg/day as an adjunctive to clozapine or olanzapine therapy, in 70 schizophrenia subjects to examine telmisartan's effect on glucose metabolism, weight, food intake, resting energy expenditure, and body composit...
What is the current status of trial NCT00981526?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2009-03. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00981526?
The interventions under investigation include: Placebo (DRUG), Olanzapine (DRUG), Clozapine (DRUG), Telmisartan (DRUG).
Who is sponsoring clinical trial NCT00981526?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.